Guangxi Medical Insurance Bureau announced that 48 drugs will be purchased in volume!

Recently, the Medical Security Bureau of Guangxi Zhuang Autonomous Region will implement the centralized procurement of drugs with a total of 48 varieties starting from 21 this month The 48 varieties include: 1 The state organizes the centralized purchase and use of 25 varieties (i.e the national "4 + 7" expanded varieties) 2 23 varieties selected by Guangxi Pharmaceutical Group (the first batch) There are 48 varieties According to the unified deployment of the state and the actual work of our district, our district will implement the centralized drug purchase with a large quantity from the end of this month The relevant matters are hereby announced as follows: The first is the 25 varieties (i.e the national "4 + 7" expanded varieties) that the state has organized to purchase and use drugs intensively, and the second is the 23 varieties selected by Guangxi Pharmaceutical Group (the first batch), a total of 48 varieties See the attachment for the detailed varieties This volume purchase will be implemented from December 21, 2019 to the time specified in the purchase agreement （1） Public designated medical institutions that have submitted the committed purchase volume （2） The manufacturer of the selected drugs who has completed the tripartite contract of purchase, sale and distribution services for the selected drugs of Guangxi Pharmaceutical Group （3） The distribution enterprise selected by the selected pharmaceutical manufacturer （4） Voluntary participation in private medical institutions and retail pharmacies with purchasing volume （1） On December 13, the information publicity of Guangxi Pharmaceutical Group's purchase and distribution enterprises (the first batch) ended 14 to deal with complaints and make an announcement （2） From December 14 to 17, drug manufacturers checked the distribution enterprises on the purchase service platform of Guangxi Pharmaceutical Group (official website of the platform: http://www.gxgpo.com) Each drug manufacturer can select 3 to 6 distribution enterprises (at least 3 at the same time) to be responsible for regional distribution The production enterprises can not distribute by themselves within the scope of 3 to 6 quotas （3） From December 18 to 20, the designated public medical institutions directly under the district government checked the distribution enterprises on the purchase service platform of Guangxi Pharmaceutical Group, and each medical institution selected one of the distribution enterprises selected by the drug manufacturers to carry out the distribution business; signed the purchase, sale and distribution of drugs purchased by Guangxi Pharmaceutical Group on the purchase service platform of Guangxi pharmaceutical group with the drug manufacturers and distribution enterprises Service tripartite contract Public designated medical institutions directly under the district shall sign the tripartite contract for purchase, sale and distribution services of Guangxi Pharmaceutical Group in accordance with the requirements of signing electronic contracts and commitments （4） Before December 20, 2019, the public designated medical institutions directly under the district participating in the volume procurement shall promptly digest the purchased stocks and select drugs Public designated medical institutions directly under the district that have completed the tripartite contract of drug purchase, sale and distribution services shall handle it in accordance with the following provisions: （1） From December 21, 2019, the selected drugs will carry out the procurement business through the procurement service platform of Guangxi Pharmaceutical Group （2） From December 21 to 31, 2019, the district directly designated public medical institutions can carry out "zero plus" sales according to the original price for the selected drugs purchased before the stock clearing period, and continue to be distributed by the original distribution enterprises （3） From January 1, 2020, the public designated medical institutions directly under the district government can not purchase and sell the selected drugs at non selected prices They must carry out "zero plus" sales according to the selected prices and carry out distribution according to the newly signed agreements From December 21 to 31, 2019, the medical insurance payment for all kinds of drugs shall be in accordance with the original standards From January 1, 2020, for the drugs purchased by the state in a centralized way, the selected price shall be taken as the payment standard of medical insurance within the scope of the medical insurance catalog For the original research drugs, reference preparations and generic drugs passing the consistency evaluation under the same general name, the medical insurance fund shall be settled according to the same payment standard For the drugs whose price is higher than the payment standard, the part exceeding the payment standard shall be paid by the patients themselves If the price difference is large (more than twice of the price selected), the payment standard can be adjusted gradually, and adjusted in place within three years (that is, in 2020, the payment standard shall be no less than 30% lower than the original price, and in 2021, the payment standard shall be no less than 30% lower than the price in 2020), In 2022, the price of the selected drugs will be reduced to the payment standard; the drugs used by patients whose price is lower than the payment standard will be paid according to the actual price From January 1, 2020, the payment standards for the first batch of selected and non selected varieties purchased by Guangxi Pharmaceutical Group shall be implemented according to the original payment standards before the new documents of the medical insurance Department of the autonomous region are issued Arrange the purchase batch and quantity reasonably It is suggested that medical institutions at all levels should comprehensively consider the needs of drug security during the new year's festival to ensure that the first purchase can meet the needs of use At the same time, in order to alleviate the pressure of goods preparation and distribution of distribution enterprises, it is suggested that the first purchase volume of medical institutions at or above level 2 shall not exceed 10% of the total annual purchase volume, and the first purchase volume of medical institutions at or below level 1 shall not exceed 25% of the total annual purchase volume.